JPWO2019175368A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175368A5 JPWO2019175368A5 JP2020548991A JP2020548991A JPWO2019175368A5 JP WO2019175368 A5 JPWO2019175368 A5 JP WO2019175368A5 JP 2020548991 A JP2020548991 A JP 2020548991A JP 2020548991 A JP2020548991 A JP 2020548991A JP WO2019175368 A5 JPWO2019175368 A5 JP WO2019175368A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- acid sequence
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000025171 antigen binding proteins Human genes 0.000 claims 17
- 108091000831 antigen binding proteins Proteins 0.000 claims 17
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 12
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 12
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 12
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 claims 11
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161871 | 2018-03-14 | ||
| EP18161871.1 | 2018-03-14 | ||
| PCT/EP2019/056516 WO2019175368A1 (en) | 2018-03-14 | 2019-03-14 | Bispecific egfr/cd16 antigen-binding protein |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021515798A JP2021515798A (ja) | 2021-06-24 |
| JPWO2019175368A5 true JPWO2019175368A5 (https=) | 2022-03-15 |
| JP2021515798A5 JP2021515798A5 (https=) | 2022-03-15 |
| JP7288913B2 JP7288913B2 (ja) | 2023-06-08 |
Family
ID=61683598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548991A Active JP7288913B2 (ja) | 2018-03-14 | 2019-03-14 | 二重特異性egfr/cd16抗原結合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11510972B2 (https=) |
| EP (1) | EP3765157A1 (https=) |
| JP (1) | JP7288913B2 (https=) |
| KR (1) | KR102924742B1 (https=) |
| CN (1) | CN111971090B (https=) |
| AU (1) | AU2019235433B2 (https=) |
| BR (1) | BR112020018492A2 (https=) |
| CA (1) | CA3090464A1 (https=) |
| IL (1) | IL276903B2 (https=) |
| MX (1) | MX2020009445A (https=) |
| SG (1) | SG11202007664WA (https=) |
| WO (1) | WO2019175368A1 (https=) |
| ZA (1) | ZA202006247B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276903B2 (en) * | 2018-03-14 | 2025-12-01 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
| KR20220119467A (ko) | 2019-12-27 | 2022-08-29 | 아피메트 게엠베하 | 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법 |
| WO2023006082A1 (zh) * | 2021-07-30 | 2023-02-02 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN116143942A (zh) * | 2021-09-09 | 2023-05-23 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| JP2024543828A (ja) * | 2021-11-03 | 2024-11-26 | アフィメド ゲーエムベーハー | 二重特異性cd16aバインダー |
| AU2022382368A1 (en) * | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
| WO2024186092A1 (ko) * | 2023-03-06 | 2024-09-12 | 주식회사 드노보 바이오테라퓨틱스 | 신규한 항-cd16 항체 및 이의 용도 |
| WO2024213097A1 (zh) * | 2023-04-14 | 2024-10-17 | 山东先声生物制药有限公司 | 一种靶向人cd16和肿瘤抗原的多特异性抗体 |
| WO2025167357A1 (zh) * | 2024-02-06 | 2025-08-14 | 启愈生物技术(上海)有限公司 | Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用 |
| CN118221818B (zh) * | 2024-04-29 | 2025-01-24 | 四川大学 | 一种抗cd16a的纳米抗体及其应用 |
| WO2026017120A1 (zh) * | 2024-07-18 | 2026-01-22 | 信达生物制药(苏州)有限公司 | 抗cdh17/egfr/cd16a三特异性抗体及其用途 |
| CN118994409B (zh) * | 2024-07-30 | 2025-07-22 | 郑州市乘黄生物医药科技有限公司 | 结合CD16A和Trop2的双特异性抗体-NK细胞偶联物及其用途 |
| CN118791616A (zh) * | 2024-09-14 | 2024-10-18 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd16工程抗体及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8289183B1 (en) | 2008-04-25 | 2012-10-16 | Texas Instruments Incorporated | System and method for solar panel array analysis |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| CN105153307A (zh) * | 2010-05-04 | 2015-12-16 | 梅里麦克制药股份有限公司 | 抗表皮生长因子受体(egfr)的抗体及其用途 |
| LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| AU2014227638A1 (en) | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| CN105555804B (zh) * | 2013-08-07 | 2020-12-25 | 阿菲姆德股份有限公司 | 对EGFRvIII有特异性的抗体结合位点 |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| ES2754557T3 (es) * | 2015-05-04 | 2020-04-20 | Affimed Gmbh | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia |
| EP3156417A1 (en) | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| IL276903B2 (en) * | 2018-03-14 | 2025-12-01 | Affimed Gmbh | Bispecific egfr/cd16 antigen-binding protein |
-
2019
- 2019-03-14 IL IL276903A patent/IL276903B2/en unknown
- 2019-03-14 SG SG11202007664WA patent/SG11202007664WA/en unknown
- 2019-03-14 WO PCT/EP2019/056516 patent/WO2019175368A1/en not_active Ceased
- 2019-03-14 BR BR112020018492-6A patent/BR112020018492A2/pt unknown
- 2019-03-14 KR KR1020207029239A patent/KR102924742B1/ko active Active
- 2019-03-14 EP EP19715401.6A patent/EP3765157A1/en active Pending
- 2019-03-14 CN CN201980018525.9A patent/CN111971090B/zh active Active
- 2019-03-14 JP JP2020548991A patent/JP7288913B2/ja active Active
- 2019-03-14 MX MX2020009445A patent/MX2020009445A/es unknown
- 2019-03-14 AU AU2019235433A patent/AU2019235433B2/en active Active
- 2019-03-14 CA CA3090464A patent/CA3090464A1/en active Pending
-
2020
- 2020-09-02 US US17/010,622 patent/US11510972B2/en active Active
- 2020-10-08 ZA ZA2020/06247A patent/ZA202006247B/en unknown
-
2022
- 2022-10-19 US US18/047,917 patent/US12076384B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515798A5 (https=) | ||
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| JP2021042257A5 (https=) | ||
| JP2021503455A5 (https=) | ||
| JP2020180158A5 (https=) | ||
| JP2020063262A5 (https=) | ||
| JP2020114210A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| JP2020533311A5 (ja) | NKG2D、CD16およびNectin4に結合するタンパク質 | |
| JP2013515508A5 (https=) | ||
| JPWO2019137548A5 (https=) | ||
| JPWO2019129221A5 (https=) | ||
| JP2010502183A5 (https=) | ||
| JPWO2019175368A5 (https=) | ||
| KR20200013230A (ko) | 적어도 cd3 및 hsa를 표적화하는 헤테로-이량체 다중 특이적 항체 포맷 | |
| JP2024113040A5 (https=) | ||
| JP2025160226A5 (https=) | ||
| JP2021512604A5 (https=) | ||
| JPWO2022042488A5 (https=) | ||
| JPWO2021064137A5 (https=) | ||
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2022111425A5 (https=) | ||
| JPWO2021030680A5 (https=) | ||
| JPWO2022268192A5 (https=) | ||
| JPWO2020073131A5 (https=) |